background
although
modifi
live
viru
mlv
vaccin
commonli
use
porcin
reproduct
respiratori
syndrom
viru
prrsv
control
safeti
concern
due
quick
revers
mlv
virul
replic
pig
previou
studi
demonstr
mutant
virus
emerg
lethal
mutagenesi
driven
antivir
mutagen
virus
higher
genet
stabil
compar
parent
strain
acquir
resist
random
mutat
thu
strategi
explor
stabil
prrsv
genom
current
studi
result
four
antivir
mutagen
ribavirin
amilorid
evalu
antivir
effect
prototyp
type
prrsv
among
mutagen
ribavirin
signific
antivir
effect
consequ
serial
passag
cell
presenc
ribavirin
sever
concentr
facilit
emerg
ribavirinresist
mutant
two
ribavirinresist
mutant
emerg
serial
passag
presenc
mm
ribavirin
respect
genet
stabil
resist
mutant
evalu
cell
compar
expect
ribavirinresist
mutant
exhibit
higher
genet
stabil
compar
parent
viru
conclus
summari
ribavirin
effect
suppress
prrsv
replic
cell
howev
ribavirinresist
mutant
emerg
treat
low
concentr
mm
ribavirin
mutant
genet
stabl
serial
passag
cell
cultur
porcin
reproduct
respiratori
syndrom
prr
one
econom
import
infecti
diseas
swine
worldwid
annual
loss
associ
prr
unit
state
swine
industri
estim
approxim
million
usd
prr
viru
prrsv
etiolog
agent
prr
classifi
member
arterivirida
viru
famili
along
equin
arter
viru
eav
lactat
dehydrogenaseelev
viru
ldv
mice
simian
hemorrhag
fever
viru
shfv
belong
order
nidoviral
prrsv
small
envelop
viru
contain
singlestrand
nonseg
positivesens
rna
genom
approxim
kb
length
prrsv
genom
encod
least
ten
open
read
frame
orf
design
prrsv
evolv
quickli
great
deal
genet
variabl
among
prrsv
strain
gener
prrsv
strain
group
european
type
north
american
type
genotyp
high
level
genet
variabl
still
exist
among
virus
even
within
genotyp
result
suboptim
crossprotect
differ
prrsv
strain
becom
signific
impedi
develop
effect
vaccin
modifi
live
viru
mlv
vaccin
commonli
use
control
prrsv
confer
better
protect
homolog
viru
strain
compar
inactiv
recombin
vaccin
howev
seriou
safeti
concern
use
mlv
vaccin
quickli
revert
virul
serial
passag
pig
therefor
import
develop
new
strategi
stabil
prrsv
genom
viru
replic
purpos
vaccin
safeti
previous
number
nucleosid
analog
includ
ribavirin
guanosin
analog
pyrimidin
analog
cytidin
analog
shown
mutagen
antivir
compound
effect
variou
rna
virus
footandmouth
diseas
viru
fmdv
polioviru
hepat
c
viru
hcv
mutagen
increas
mutat
frequenc
rna
virus
toler
error
threshold
replic
ultim
drive
viral
infect
extinct
amilorid
hydrochlorid
hydrat
hereaft
amilorid
anoth
antivir
drug
efficaci
mani
rna
virus
includ
rhinoviru
coxsackieviru
coronavirus
flavivirus
retrovirus
moreov
demonstr
amilorid
increas
mutat
frequenc
rna
virus
addit
antivir
activ
also
demonstr
mutant
virus
emerg
follow
sequenti
passag
hcv
polioviru
fmdv
presenc
ribavirin
higher
genet
stabil
wildtyp
virus
therefor
strategi
employ
select
mutagenresist
strain
prrsv
would
higher
genet
stabil
current
studi
effect
four
mutagen
ribavirin
amilorid
prrsv
replic
cell
evalu
select
mutagen
effect
prrsv
mutagenresist
virus
rescu
sequenti
passag
presenc
mutagen
evalu
genet
stabil
addit
sequenti
passag
cell
cultur
system
ribavirin
sigmaaldrich
st
loui
mo
usa
sigmaaldrich
sigmaaldrich
amilorid
sigmaaldrich
use
studi
mutagen
dissolv
medium
sigmaaldrich
stock
concentr
mm
ribavirin
mm
amilorid
sterilefilt
use
syring
filter
aliquot
store
use
viru
cell
cultur
prototyp
strain
prrsv
type
use
studi
african
green
monkey
kidney
cell
line
highli
permiss
prrsv
infect
use
prrsv
propag
antivir
assay
cell
maintain
medium
supplement
heatinactiv
fetal
bovin
serum
fb
invitrogen
carlsbad
ca
usa
mm
lglutamin
antibioticantimycot
solut
antianti
invitrogen
solut
contain
iuml
penicillin
streptomycin
amphotericin
b
hereaft
refer
rpmi
growth
medium
humidifi
co
atmospher
confluent
monolay
cell
prepar
flask
inocul
multipl
infect
moi
incub
hour
humidifi
co
incub
viru
inoculum
remov
cell
monolay
replenish
rpmi
growth
medium
contain
one
antivir
mutagen
ribavirin
amilorid
evalu
six
differ
concentr
mm
evalu
ten
differ
concentr
mm
base
previou
report
treat
flask
incub
four
day
cultur
condit
describ
time
cell
cultur
medium
collect
flask
everi
hour
centrifug
store
analysi
progeni
viru
titer
determin
use
microtitr
infect
assay
brief
serial
dilut
sampl
prepar
confluent
monolay
cell
prepar
plate
inocul
quadrupl
sampl
incub
hour
cultur
condit
describ
incub
inoculum
discard
cell
monolay
replenish
rpmi
growth
medium
plate
incub
addit
six
day
monitor
cytopath
effect
cpe
daili
titer
viru
sampl
calcul
base
cpe
express
tissu
cultur
infect
dose
tcid
ml
commerci
avail
cytotox
assay
kit
promega
fitchburg
wisconsin
usa
use
assess
cytotox
effect
four
antivir
mutagen
cell
short
assay
measur
distinct
proteas
deadcel
proteas
activ
associ
cytotox
assay
use
luminogen
peptid
substrat
alanylalanylphenylalanylaminoluciferin
substrat
measur
activ
deadcel
proteas
releas
cell
lost
membran
integr
determin
cytotox
mutagen
confluent
monolay
cell
prepar
flask
rins
cell
replenish
rpmi
growth
medium
contain
one
mutagen
one
four
differ
concentr
mm
incub
cultur
condit
describ
supernat
collect
flask
everi
hour
hour
level
luminesc
rlu
gener
cleavag
luminogen
substrat
proteas
collect
supernat
measur
determin
cytotox
level
induc
mutagen
accord
manufactur
instruct
serial
passag
cell
cultur
presenc
mm
ribavirin
studi
emerg
ribavirinresist
prrsv
mutant
confluent
monolay
cell
prepar
plate
pretreat
rpmi
growth
medium
contain
ribavirin
hour
prior
infect
pretreat
incub
cell
inocul
moi
incub
hour
viru
inoculum
remov
cell
replenish
rpmi
growth
medium
contain
concentr
ribavirin
describ
posttreat
infect
allow
proceed
hour
cell
cultur
fluid
collect
well
centrifug
store
use
supernat
passag
becam
inoculum
next
passag
procedur
repeat
total
time
assess
growth
kinet
ribavirinresist
mutant
presenc
ribavirin
sever
concentr
use
multistep
growth
curv
analysi
growth
compet
two
ribavirinresist
candid
mutant
assess
cell
presenc
ribavirin
compar
presenc
ribavirin
confluent
monolay
cell
prepar
flask
inocul
viru
moi
incub
hour
condit
describ
incub
inoculum
discard
cell
replenish
growth
medium
contain
sever
concentr
mm
ribavirin
treat
flask
incub
day
supernat
collect
flask
everi
hour
viru
supernat
titer
assess
genet
stabil
ribavirinresist
mutant
aros
sequenti
passag
presenc
ribavirin
describ
mutant
virus
passag
time
along
plaqu
purif
perform
use
strain
achiev
highli
homogen
viru
clone
describ
previous
passag
confluent
cell
monolay
prepar
plate
inocul
viru
strain
incub
hour
incub
cell
replenish
rpmi
growth
medium
incub
hour
supernat
collect
use
next
passag
cell
procedur
repeat
time
plaqu
purif
conduct
supernat
collect
passag
isol
plaqu
clone
per
viral
strain
viral
rna
extract
viru
clone
use
commerci
kit
ribospin
geneal
seoul
south
korea
accord
manufactur
instruct
known
variabl
region
prrsv
genom
amplifi
onestep
rtpcr
kit
takara
bio
inc
otsu
shiga
japan
submit
sequenc
macrogen
inc
south
korea
pcr
amplif
sequenc
primer
shown
tabl
effect
four
mutagen
prrsv
replic
analyz
repeat
measur
analysi
varianc
anova
wilcoxon
signedrank
test
use
compar
mutat
rate
ribavirinresist
mutant
parent
viru
strain
nucleotid
sequenc
align
analyz
use
magalign
softwar
dnastar
inc
madison
wi
usa
effect
four
antivir
mutagen
studi
prrsv
replic
summar
figur
rate
replic
cell
decreas
presenc
mm
ribavirin
complet
suppress
concentr
ribavirin
higher
mm
despit
effici
antivir
effect
ribavirin
low
concentr
signific
cytotox
observ
even
highest
concentr
mutant
viru
strain
exhibit
higher
replic
effici
presenc
ribavirin
figur
replic
effici
presenc
mm
ribavirin
respect
moreov
unabl
replic
presenc
ribavirin
concentr
mm
higher
wherea
abl
grow
moder
extent
presenc
ribavirin
concentr
high
mm
ribavirinresist
mutant
plaquepurifi
design
respect
plaquepurifi
virus
serial
passag
time
cell
without
ribavirin
passag
viru
clone
rescu
supernat
plaqu
purif
viru
strain
hypervari
region
viru
clone
amplifi
sequenc
summar
tabl
figur
exhibit
lower
mutat
frequenc
sequenti
passag
cell
nucleotid
amino
acid
substitut
identifi
region
wherea
nucleotid
p
amino
acid
substitut
p
nucleotid
p
amino
acid
substitut
p
region
figur
similar
mutat
frequenc
nucleotid
amino
acid
substitut
nucleotid
amino
acid
substitut
current
studi
possibl
rescu
genet
stabl
prrsv
mutant
sequenti
passag
cell
presenc
mutagen
explor
basi
previou
report
show
mutant
virus
emerg
lethal
mutagenesi
driven
antivir
mutagen
exhibit
higher
genet
stabil
wildtyp
virus
choos
appropri
mutagen
studi
four
differ
antivir
mutagen
ribavirin
amilorid
evalu
antivir
effect
prrsv
cytotox
cell
presenc
ribavirin
concentr
higher
mm
replic
complet
suppress
wherea
even
highest
concentr
mm
ribavirin
caus
signific
cytotox
cell
figur
b
result
good
agreement
previou
studi
conduct
evalu
antivir
effect
ribavirin
sever
rna
virus
includ
hcv
respiratori
syncyti
viru
rsv
polioviru
fmdv
influenza
b
virus
recent
ribavirin
report
potenti
antivir
drug
prrsv
reduc
viru
replic
approxim
time
cell
ad
concentr
mm
highest
concentr
appli
studi
howev
current
studi
mm
ribavirin
fail
suppress
prrsv
replic
cell
concentr
higher
mm
ribavirin
requir
complet
suppress
prrsv
replic
figur
unlik
result
observ
cell
signific
cytotox
observ
cell
even
treat
mm
ribavirin
thu
ribavirinresist
mutant
virus
rescu
presenc
ribavirin
concentr
high
mm
similarli
effect
suppress
replic
cell
concentr
rang
mm
without
caus
signific
cytotox
figur
c
effect
antivir
activ
also
report
rift
valley
fever
viru
vesicular
stomat
viru
polioviru
fmdv
contrast
amilorid
concentr
mm
induc
signific
cytotox
cell
although
concentr
amilorid
lower
mm
show
substanti
antivir
efficaci
prrsv
figur
e
f
figur
g
h
previou
studi
report
mm
caus
signific
cytotox
cell
hour
treatment
although
signific
level
antivir
activ
report
concentr
howev
low
concentr
mm
result
signific
antivir
activ
prrsv
current
studi
data
shown
previou
studi
report
mm
amilorid
noncytotox
hela
cell
hour
posttreat
conflict
result
observ
studi
show
substanti
cytotox
observ
mm
amilorid
cell
hour
posttreat
figur
h
specul
dissimilar
might
due
differ
origin
cell
line
use
studi
base
initi
assess
antivir
mutagen
ribavirin
select
studi
evalu
possibl
emerg
ribavirinresist
mutant
show
greatest
effect
prrsv
replic
without
caus
signific
cytotox
even
highest
concentr
mm
two
ribavirinresist
mutant
isol
passag
serial
passag
cell
presenc
mm
ribavirin
respect
figur
previou
studi
also
report
emerg
ribavirinresist
mutant
ribavirinresist
hcv
emerg
passag
cell
cultur
mm
ribavirin
similarli
ribavirinresist
polioviru
fmdv
emerg
sequenti
passag
hela
cell
cultur
mm
ribavirin
growth
compet
ribavirinresist
mutant
cell
assess
presenc
absenc
ribavirin
ribavirinresist
mutant
show
approxim
higher
replic
effici
presenc
mm
ribavirin
moreov
replic
complet
suppress
concentr
higher
mm
ribavirin
mutant
abl
gener
infecti
progeni
virus
reach
titer
close
tcid
ml
presenc
mm
ribavirin
figur
report
mani
previou
studi
conduct
polioviru
human
enteroviru
fmdv
coxsacki
viru
hcv
enhanc
resist
mutant
virus
ribavirin
might
associ
increas
genet
fidel
acquir
viral
passag
presenc
ribavirin
howev
higher
replic
effici
might
also
result
viru
adapt
cell
mutant
virus
rescu
sequenti
passag
fact
mutant
virus
replic
effici
tabl
mutat
frequenc
plaqueclon
ribavirinresist
mutant
passag
cell
absenc
ribavirin
compar
therefor
genet
stabil
ribavirinresist
mutant
assess
passag
mutant
virus
time
cell
without
ribavirin
parallel
demonstr
ribavirinresist
mutant
increas
genet
stabil
variabl
gene
prrsv
genom
sequenc
determin
mutat
frequenc
virus
sequenti
passag
viru
clone
exhibit
lower
number
nucleotid
substitut
lower
number
amino
acid
substitut
respect
region
compar
viru
clone
tabl
figur
region
viru
clone
exhibit
mutat
rate
similar
observ
viru
clone
viru
clone
approxim
lower
number
nucleotid
substitut
lower
number
amino
acid
substitut
compar
viru
clone
tabl
figur
b
base
result
conclud
ribavirinresist
mutant
especi
significantli
higher
genet
stabil
compar
parent
viru
conclus
ribavirin
effect
suppress
prrsv
replic
cell
concentr
higher
mm
suggest
ribavirin
could
use
therapeut
drug
prrsv
howev
potenti
use
prrsv
infect
remain
confirm
anim
studi
describ
current
studi
resist
virus
emerg
presenc
low
concentr
mm
ribavirin
resist
virus
significantli
higher
genet
stabil
compar
rapid
revers
attenu
prr
vaccin
virul
great
concern
higher
level
genet
stabil
could
good
candid
develop
safer
vaccin
nonetheless
mechan
genet
determin
respons
high
genet
stabil
ribavirinresist
prrsv
elucid
detail
near
futur
vitro
assess
genet
stabil
ribavirinresist
prrsv
mutant
serial
passag
cell
genet
stabil
plaquepurifi
ribavirinresist
mutant
compar
plaquepurifi
passag
cell
fifteen
viral
clone
obtain
cell
cultur
fluid
collect
complet
passag
viru
plaqu
purif
b
region
viru
clone
sequenc
compar
parent
virus
determin
nucleotid
mutat
amino
acid
b
substitut
sequenti
passag
asterisk
repres
signific
differ
mutat
rate
compar
p
p
